Banyan Biomarkers, Inc. is creating the first blood test to diagnose traumatic brain injury (TBI). Currently, there is no objective test that exists to detect the presence and severity of brain trauma. Banyan Biomarkers' research has identified unique and proprietary biomarkers present in the patient's blood following injury to the brain. The detection and quantification of these biomarkers may provide early indications of brain trauma essential for earlier intervention and management.
There are over 70 peer-reviewed publications specific to the company’s assays for the detection of neural injury. These same biomarkers may have the ability to distinguish between stroke and stroke mimics and also provide relative updates on the condition of patients in the neuro-ICU.